Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African–American patients: A subgroup analysis of a randomized phase 4 study

Conclusion: In PREFERMS, fingolimod was associated with better treatment retention than iDMTs in African–American patients. Optimal outcomes in the management of multiple sclerosis depend on good persistence with treatment, and this is particularly important in patient populations at increased risk of a rapidly progressing disease course.Trial Registration: NCT01623596.Funding: Novartis Pharmaceuticals Corporation.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research